3 registrations that name red yeast rice as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
All 3 registrations
RecruitingNCT07106996
Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome
Early phase 1
Sichuan Provincial People's Hospital
About 90 people
Started Jul 28, 2025
In plain words An early phase 1 study of red yeast rice in female participants 18 to 40, run by Sichuan Provincial People's Hospital. It plans to enroll about 90 people at 1 site, none in the US.
Meeting the Rotterdam criteria (at least two of the following):
Anovulation or oligo-ovulation
Clinical evidence of hyperandrogenism or hyperandrogenemia
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
red yeast rice，RYR
Registered summary
The aim of this study is to elucidate the effects of red yeast rice on the improvement of symptoms in patients with polycystic ovary syndrome（PCOS）, and to analyze the dose-response relationship between intestinal microbiota and its metabolite, hydroxyindole, and clinical indicators of PCOS. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT05737342
Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose
No phase
SunWay Biotech Co., LTD.
About 80 people
Started Apr 1, 2023
In plain words A study of red yeast rice in people 20 and older, run by SunWay Biotech Co., LTD.. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: High Blood Sugar; Metabolic Syndrome.
Men or non-pregnant women over 20 years old (women of childbearing age are not allowed to become pregnant or breastfeed during the study) adults who are sane and able to communicate.
18≦BMI≦35.
Blood routine examination (CBC; Complete blood count): the mean corpuscular volume MCV should not be less than 70 fL.
Blood glucose level measurement meets any of the following conditions: (1) The fasting blood sugar is between 100∼125 mg/dL, and the doctor judges that there is no need to use hypoglycemic drugs for the time being.
The exclusion criteria are on the listing.
What it tests, as registered
ANKASCIN 568-P Red yeast rice capsules; Placebo Capsules
Registered summary
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
Where, as registered
No US site; Taiwan (1).
RecruitingNCT05737355
Effect of ANKASCIN 568-P Products Regulating Blood Lipid
No phase
SunWay Biotech Co., LTD.
About 80 people
Started Apr 1, 2023
In plain words A study of red yeast rice in people 20 and older, run by SunWay Biotech Co., LTD.. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Hyperlipidemias.
Male or Female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period).
A sane and communicative adult.
18≦BMI≦35.
Sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
ANKASCIN 568-P Red yeast rice capsules; Placebo Capsules
Registered summary
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)